Table 2.
Treatment of hepatitis C cirrhosis with triple therapy
| Fibrosis stage | Drug | Prior PEG-IFN responsiveness (n) | Treatment response | Serious adverse events1 | Ref. |
| Cirrhosis | Telaprevir | 21 | 62% SVR | 9% | [4] |
| Bridging fibrosis and cirrhosis | Boceprevir | 76 | 47% SVR | 12% | [5] |
| Relapse (n = 119) | 85% SVR | ||||
| Partial response (n = 50) | 42% SVR | ||||
| Null response (n = 88) | 24% SVR | ||||
| Bridging fibrosis and cirrhosis | Boceprevir | Relapse and partial response (n = 63) | 56% SVR | 12% | [7] |
| Child A | Telaprevir | 285 | 67% (16 wk) | 45% | [8] |
| Boceprevir | 204 | 58% (16 wk) | 33% |
1
Serious adverse event rate for entire study population, % of patients with undetectable hepatitis C virus RNA at 16 wk following drug initiation, an interim analysis. PEG-IFN: Pegylated-interferon; SVR: Sustained viral response rate.